Bulletin du cancer最新文献

[Haploidentical hematopoietic stem cell transplantation in the treatment of pediatric hematological malignancies (SFGM-TC)]. [单倍体造血干细胞移植治疗儿童血液系统恶性肿瘤（SFGM-TC）]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-24 DOI: 10.1016/j.bulcan.2025.07.015

Anne Sirvent, Marie Angoso, Charlotte Calvo, Ana Berceanu, Asma El Quessar, Catherine Fabaron, Jean Sébastien Diana, Dina Ait, Qamrani Fadwa, Maria El Kababri, Catherine Paillard

{"title":"[Haploidentical hematopoietic stem cell transplantation in the treatment of pediatric hematological malignancies (SFGM-TC)].","authors":"Anne Sirvent, Marie Angoso, Charlotte Calvo, Ana Berceanu, Asma El Quessar, Catherine Fabaron, Jean Sébastien Diana, Dina Ait, Qamrani Fadwa, Maria El Kababri, Catherine Paillard","doi":"10.1016/j.bulcan.2025.07.015","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.07.015","url":null,"abstract":"The use of haploidentical Hematopoietic Stem Cell Transplants (Haplo-HSCT) in adults has increased due to improved procedures that lower the risk of graft-versus-host disease (GvHD) and Transplant-Related Mortality (TRM). In pediatrics, haploidentical transplants, whether performed with in vivo or in vitro T-cell depletion, are considered an alternative to conventional transplants from genoidentical or phenoidentical donors with bone marrow (BM), peripheral stem cell (PBSC). This review synthesizes current knowledge, highlighting a thorough analysis of pediatric data from Haplo-HSCT for malignancies. In brief, donor selection criteria are the same as those published for adults, and the conditioning used is primarily myeloablative. The incidence of severe GvHD is lower as compared to adults, but other complications, such as hemorrhagic cystitis, veno-occusive disease and cardiac toxicity are present, and long-term follow-up data is lacking. We provide comprehensive recommendations for transplant preparation in treating pediatric AML and ALL, focusing on the \"in vivo\" T-cell depletion approach with high-dose post-transplant cyclophosphamide (PT-Cy).","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Epidemiology of paediatric cancers in French-speaking Africa. The GFAOP hospital register]. 法语非洲儿童癌症流行病学研究。GFAOP医院登记]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-24 DOI: 10.1016/j.bulcan.2025.07.010

Brenda Mallon, Aissata Barry, Rolande Kabore, Erick Mbokoya Kokanya, Francis Diedhiou, Thomas Nihouarn, Isabelle Champenois, Anne Gagnepain Lacheteau, Laila Hessissen, Catherine Patte

{"title":"[Epidemiology of paediatric cancers in French-speaking Africa. The GFAOP hospital register].","authors":"Brenda Mallon, Aissata Barry, Rolande Kabore, Erick Mbokoya Kokanya, Francis Diedhiou, Thomas Nihouarn, Isabelle Champenois, Anne Gagnepain Lacheteau, Laila Hessissen, Catherine Patte","doi":"10.1016/j.bulcan.2025.07.010","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.07.010","url":null,"abstract":"In Francophone Africa (343 million inhabitants in 2024, 42% under 15 years of age), childhood cancer is under-documented. The French African Paediatric Oncology Group (GFAOP) launched a centralized hospital registry project (RFAOP) in 2016 to improve knowledge, structure the needs of paediatric oncology units, and address the lack of reliable information. Here, we describe this unique Registry, explaining what has been learned and its impact. Analyses of the Registry (2016-2019) reveal diagnostic disparities and a lack of correlation between the number of cases and the population, highlighting significant needs in human and material resources and underscoring the necessity for targeted investments. The Registry tracks cancer trends, and documents prevalent types of cancer, such as Burkitt's lymphoma in some regions, and very low numbers of brain tumours especially in the sub-Saharan region. The stage and extent of the disease at diagnosis is also discussed. Inter-unit heterogeneities and a hospital registry bias are noted. The application of staging guidelines has improved data quality, but late diagnoses persist with high percentages of advanced stage disease. Follow-up of survival 57% at 12 months is discussed, but encouraging rates are observed for certain cancers. Treatment abandonment is a major problem being studied using socio-economic and cancer type as possible contributing factors. This Registry is crucial for resource planning despite limitations in diagnosis and follow-up. On-going training and support are essential to maintain the quality of this project. It reveals disparities with global data, emphasizing the need for robust population-based registries linked to quality diagnostics and care, and for sustainable funding to ensure a lasting impact.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Considering treatments' proportionality at the advanced phase of the disease: A structuring challenge for the future of oncology]. [考虑到疾病晚期的治疗比例：肿瘤学未来的结构性挑战]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-22 DOI: 10.1016/j.bulcan.2025.07.025

Jean-Christophe Mino, Pauline Vaflard, Benjamin Derbez, Carole Bouleuc, Elisabeth Lucchi, Anne Brédart, Gisèle Chvetzoff, Sylvie Dolbeault

引用次数: 0

[Adherence to adjuvant endocrine therapy in young women with breast cancer: An underused lever to improve survival]. 年轻女性乳腺癌患者坚持辅助内分泌治疗：一个未充分利用的提高生存率的杠杆。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-22 DOI: 10.1016/j.bulcan.2025.07.024

Floriane Jochum, Élise Dumas, Florence Coussy, Paul Gougis, Anne-Sophie Hamy, Cherif Akladios

引用次数: 0

[Choice of bridging therapy prior to reinjection of autologous CAR-T cells in patients aged 0-25 years treated for B-ALL (SFGM-TC)]. [0-25岁B-ALL （SFGM-TC）患者再注射自体CAR-T细胞前桥接治疗的选择]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-19 DOI: 10.1016/j.bulcan.2025.07.016

Cécile Pochon, Florence Rabian, Eolia Brissot, Paul Chauvet, Laura Olivier, Leonardo Magro, Marie-Emilie Dourthe

引用次数: 0

[Therapeutic adaptations: Rationale, achievements and limits. Experience of GFAOP]. [治疗性适应：理论基础、成就和局限。]GFAOP的经验]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-17 DOI: 10.1016/j.bulcan.2025.07.011

Gabrielle Chantal Bouda, Catherine Patte

{"title":"[Therapeutic adaptations: Rationale, achievements and limits. Experience of GFAOP].","authors":"Gabrielle Chantal Bouda, Catherine Patte","doi":"10.1016/j.bulcan.2025.07.011","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.07.011","url":null,"abstract":"In high-income countries such as in Europe, cure rate of children with cancer is high thanks to prospective therapeutic studies, generally randomized. In countries with lower income, these validated and published treatments can be difficult to apply necessitating adaptations to reduce toxicity while trying to maintain cure rate as high as possible. These adaptations to take into consideration local conditions depend on the experience of the treating unit, on the means available such as drugs, supportive care, complementary examinations, especially radiologic. Since the year 2000, GFAOP has selected for the sub-Saharan countries, 2 (Burkitt lymphoma, nephroblastoma), then 3 other pathologies (Hodgkin lymphoma, lymphoblastic leukemia, retinoblastoma) which has cure rates of 90% in France with cheap drugs. The objective of this article is to show how the adapted therapeutic recommendations (accompanied by team training and drug supply) prospectively evaluated, allowed us to know and to increase cure rates and to identify points to improve in the following studies. Among difficulties to overcome in Africa: the absence of health coverage and the late arrival of the children in the specialized units. Presently cure rate of the children who can be treated according to these recommendations are around 50-60%, trying to reach the 60% cure rate fixed by WHO for 2030.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Use of Ommaya Reservoirs in the management of acute leukemias in children and adolescents: Guidelines from the French Society for Childhood and Adolescent Cancer and Leukemia (SFCE) Committee]. [在儿童和青少年急性白血病的管理中使用Ommaya水库：法国儿童和青少年癌症和白血病协会（SFCE）委员会的指南]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-17 DOI: 10.1016/j.bulcan.2025.07.014

Annaëlle Rousseaux, Camille Leglise, Lauriane Goldwirt, Kevin Beccaria, Nimrod Buchbinder, Julien Lejeune, Guy Leverger, Arnaud Petit, Pierre Simon Rohrlich, Stéphane Ducassou, Marion Strullu

{"title":"[Use of Ommaya Reservoirs in the management of acute leukemias in children and adolescents: Guidelines from the French Society for Childhood and Adolescent Cancer and Leukemia (SFCE) Committee].","authors":"Annaëlle Rousseaux, Camille Leglise, Lauriane Goldwirt, Kevin Beccaria, Nimrod Buchbinder, Julien Lejeune, Guy Leverger, Arnaud Petit, Pierre Simon Rohrlich, Stéphane Ducassou, Marion Strullu","doi":"10.1016/j.bulcan.2025.07.014","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.07.014","url":null,"abstract":"The use of Ommaya reservoirs for intraventricular chemotherapy in pediatric acute leukemias remains heterogeneous, despite being a valuable alternative when lumbar puncture (LP) is unsuccessful or contraindicated. This study aimed to evaluate national practices and develop harmonized recommendations under the auspices of the French Society for the Fight Against Childhood and Adolescent Cancers and Leukemias (SFCE) Committee. A national 34-item questionnaire was distributed to 83 pediatric hemato-oncologists within the SFCE network, covering indications, surgical procedures, dosing, bedside practices, and complication management. Thirty-two responses from 24 centers were analyzed. The primary indication for Ommaya reservoir placement was the inability to perform LP. In cases of refractory or relapsed leukemic meningitis, pharmacokinetic data support its use due to improved methotrexate distribution in cerebrospinal fluid (CSF). A 50% dose reduction for intrathecal medications (methotrexate, cytarabine, hydrocortisone) is recommended, ensuring equivalent efficacy and improved tolerance. Strict aseptic techniques are essential to minimize infection risk (5-8%). In the event of infection, temporary removal of the device is advised. The Ommaya reservoir represents an effective and safe alternative to the lumbar route in selected cases. These recommendations aim to standardize practices and enhance patient safety.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High MRPL12 expression drives esophageal cancer proliferation, invasion and migration. MRPL12高表达驱动食管癌的增殖、侵袭和迁移。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-17 DOI: 10.1016/j.bulcan.2025.07.012

Guangxu Wang, Xiaoming Sun, Qiaoling Liu, Zhanyue Pang, Yubin Huang, Lin Lv, Houlu Zhang, Haibo Liu, Liangming Zhu

{"title":"High MRPL12 expression drives esophageal cancer proliferation, invasion and migration.","authors":"Guangxu Wang, Xiaoming Sun, Qiaoling Liu, Zhanyue Pang, Yubin Huang, Lin Lv, Houlu Zhang, Haibo Liu, Liangming Zhu","doi":"10.1016/j.bulcan.2025.07.012","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.07.012","url":null,"abstract":"Background: Mitochondrial dysfunction and metabolic reprogramming contribute to the occurrence and progression of esophageal squamous cell carcinoma (ESCC). Several studies confirmed the involvement of mitochondrial ribosomal protein L12 (MRPL12) in regulating mitochondrial metabolism. Mitochondrial ribosomal protein L7/L12 (MRPL12) is a gene that regulates mitochondrial transcription. However, its role in esophageal tumorigenesis remains unknown.Methods: MRPL12 expression in ESCC and its transcription factors were assessed by Online databases. Its expression in ESCC tissues from oesophageal cancer patients, patient-derived ESCC tissues, and cell lines was detected by western blotting, RT-qPCR and immunohistochemistry. A series of cellular experiments, including gene knockout and overexpression were performed in esophageal cancer cell lines. Scratch assay, Transwell assay and CCK-8 cell viability assay were performed to establish the proliferation and migration of esophageal cancer cell lines.Results: A significant MRPL12 upregulation was observed in ESCC cells and tissues. MRPL12 overexpression promoted cell proliferation, migration, and invasion in vitro, while MRPL12 knockout induced the opposite effect. Subsequently, the most relevant transcription factors ZNF460 and ZNF135 for MRPL12 were found by online databases.Conclusion: A new role of MRPL12 in ESCC was discovered. MRPL12 represented a potential prognostic biomarker for ESCC, and the reduction in MRPL12 expression might be a potential therapeutic approach to inhibit ESCC progression.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Ruxolitinib - Acute or chronic graft-versus-host disease after corticosteroid failure]. [Ruxolitinib -皮质类固醇失败后急性或慢性移植物抗宿主病]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-17 DOI: 10.1016/j.bulcan.2025.07.022

Lydia Cherfaoui, Michael Loschi

引用次数: 0

[Imetelstat for low and intermediate risk myelodysplastic syndromes without 5q deletion in transfusion-dependant patients]. [Imetelstat用于输注依赖患者无5q缺失的低危和中危骨髓增生异常综合征]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-17 DOI: 10.1016/j.bulcan.2025.07.023

Camille Malbrun, Maud D'Aveni

引用次数: 0